BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31662149)

  • 21. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
    Georges GE; Maris M; Sandmaier BM; Malone DG; Feinstein L; Niederweiser D; Shizuru JA; McSweeney PA; Chauncey TR; Agura E; Little MT; Sahebi F; Hegenbart U; Pulsipher MA; Bruno B; Forman S; Woolfrey AE; Radich JP; Blume KG; Storb R
    Int J Hematol; 2002 Aug; 76 Suppl 1():184-9. PubMed ID: 12430851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical developments in reduced intensity haematopoietic stem cell transplantation.
    Hogan WJ; Storb R
    Expert Opin Biol Ther; 2002 Oct; 2(7):703-14. PubMed ID: 12387669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Georges GE; Storb R
    Int J Hematol; 2003 Jan; 77(1):3-14. PubMed ID: 12568294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unrelated donor haematopoietic stem cell transplantation for adult patients with haematological malignancies.
    Huang H; Lai XY
    Hong Kong Med J; 2009 Jun; 15(3 Suppl 3):22-6. PubMed ID: 19494392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
    Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autoimmune hematological diseases following haploidentical donor hematopoietic stem cell Transplant compared with matched sibling and unrelated donor.
    Lv W; Fan Z; Huang F; Xu N; Xuan L; GuopanYu ; Jiang Q; Zhou H; Lin R; Zhang X; Sun J; Liu Q
    Oncotarget; 2017 Apr; 8(16):26505-26514. PubMed ID: 28460445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies.
    Sohn SK; Jung JT; Kim DH; Lee NY; Seo KW; Chae YS; Park SW; Kim JG; Suh JS; Lee KB
    Cancer; 2002 Jan; 94(1):18-24. PubMed ID: 11815956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autophagy and haematopoietic stem cell transplantation.
    Leveque L; Le Texier L; Lineburg KE; Hill GR; MacDonald KP
    Immunol Cell Biol; 2015 Jan; 93(1):43-50. PubMed ID: 25367185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adoptive Immunotherapies After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies.
    Xiong Y; Bensoussan D; Decot V
    Transfus Med Rev; 2015 Oct; 29(4):259-67. PubMed ID: 26282736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-myeloablative transplants for malignant disease.
    Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
    Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies.
    Luo Y; Zeng HQ; Shen Y; Zhang P; Lou SF; Chen L; Deng JC
    Leuk Res; 2016 Sep; 48():6-10. PubMed ID: 27416327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
    Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
    Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haematopoietic stem cell transplantation: current concepts and novel therapeutic strategies.
    Leung AY; Kwong YL
    Br Med Bull; 2010; 93():85-103. PubMed ID: 19900948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial.
    Locatelli F; Bernardo ME; Bertaina A; Rognoni C; Comoli P; Rovelli A; Pession A; Fagioli F; Favre C; Lanino E; Giorgiani G; Merli P; Pagliara D; Prete A; Zecca M
    Lancet Oncol; 2017 Aug; 18(8):1126-1136. PubMed ID: 28705454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapeutic effect of allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens on hematological malignancies].
    Yuan X; Sun ZM; Liu HL; Geng LQ; Wang ZY; Tong J; Yao W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):614-7. PubMed ID: 18549640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center.
    Huang X; Liu D
    Clin Transpl; 2011; ():237-45. PubMed ID: 22755417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.
    Finke J; Brugger W; Bertz H; Behringer D; Kunzmann R; Weber-Nordt RM; Kanz L; Mertelsmann R
    Bone Marrow Transplant; 1996 Dec; 18(6):1081-6. PubMed ID: 8971376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies.
    Meisel R; Laws HJ; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Schmitz M; Fischer J; Göbel U; Enczmann J; Dilloo D
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1338-45. PubMed ID: 17950920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Haematopoietic transplants combining a single unrelated cord blood unit and mobilized haematopoietic stem cells from an adult HLA-mismatched third party donor. Comparable results to transplants from HLA-identical related donors in adults with acute leukaemia and myelodysplastic syndromes.
    Sebrango A; Vicuña I; de Laiglesia A; Millán I; Bautista G; Martín-Donaire T; Regidor C; Cabrera R; Fernandez MN
    Best Pract Res Clin Haematol; 2010 Jun; 23(2):259-74. PubMed ID: 20837338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.